BPT567 / Bright Peak Therap - LARVOL DELTA

Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate (GlobeNewswire) - "Bright Peak Therapeutics...today announced that the first patient was dosed in its Phase 1/2a trial evaluating BPT567, an investigational bifunctional PD1-IL18 immunoconjugate."

Trial status • Oncology • Solid Tumor

Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials (GlobeNewswire) - "Bright Peak Therapeutics...announced that it raised $90 million in a Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, with participation from additional new investors Venrock, KB Investment, and Northleaf Capital Partners. Existing investors participating in the round include founding investor Versant Ventures along with Fidelity Management & Research Company, RA Capital Management, Qatar Investment Authority, Invus, Alexandria Venture Investments, and an undisclosed leading healthcare investment fund. Proceeds from the Series C financing will be used to advance BPT567 into a Phase 1/2a clinical trial and accelerate a pipeline of next-generation immunotherapies."

Financing • Oncology • Solid Tumor

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Bright Peak Therapeutics...today announced the presentation of new data characterizing the mechanisms of action, and potent preclinical antitumor activity of BPT567, a cis-signaling, PD1-IL18 immunoconjugate, at the American Association for Cancer Research (AACR) Annual Meeting being held on April 4-10, 2024, in San Diego, CA....'Characterization of the biological activity of BPT567 in preclinical tumor models has demonstrated that BPT567 indeed can more selectively target the potent proinflammatory effects of IL-18 to the tumor.'"

Preclinical • Oncology

A first-in-class PD1-IL18 immunocytokine (BPT567) targets PD-1+ IL18R+ CD8+ T effector cells enriched in the tumor microenvironment and exhibits potent antitumor efficacy with excellent tolerability (AACR 2023) - "Hence, we developed a PD1-IL18 IC to specifically target and activate intratumoral IL-18R-expressing PD-1+ CD8+ T cells.We engineered a conjugatable variant of human IL-18 with enhanced potency and significant resistance to IL-18 binding protein (IL-18BP) and utilized this enhanced IL-18 payload to create a PD1-IL18 IC (BPT567) via site-specific chemical conjugation to a defined lysine residue within the heavy chain of an anti-human PD-1 antibody (Ab)...Our evidence suggests that the strong in vivo efficacy observed is attributed to a preferential activation of PD-1+ tumor-infiltrated immune cells. The excellent tolerability and large therapeutic window observed in mice may be driven by less potent immune cell activation in the periphery."

Biomarker • Clinical • IO biomarker • Tumor microenvironment • Oncology • CD8 • IL18

Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional PD1-IL18 Immunocytokine (GlobeNewswire) - "Bright Peak Therapeutics...announced the presentation of new data characterizing the highly targeted biological and therapeutic effects of BPT567 that contribute to its potent single agent anti-tumor activity at the American Association for Cancer Research (AACR) Annual Meeting being held on April 14-19, 2023, in Orlando, FL....In preclinical tumor models, administration of BPT567 mediated synergistic antitumor activity that was superior to anti-PD-1 alone, a control non-targeted HER2 IL-18 IC, or the combination of anti-PD-1 and non-targeted IL-18 IC. All mice that were cured of their initial tumors rejected rechallenge with MC38 implantation, confirming the development of long-term immunologic memory induced by BPT567."

Preclinical • Oncology